Reuters logo
BRIEF-Targovax: one-year survival rate and safety data in modified cohort of TG01 trial in resected pancreatic cancer
October 12, 2017 / 5:08 AM / in 7 days

BRIEF-Targovax: one-year survival rate and safety data in modified cohort of TG01 trial in resected pancreatic cancer

Oct 12 (Reuters) - TARGOVAX ASA:

* ‍ANNOUNCES ONE-YEAR DATA ON SURVIVAL RATE, IMMUNE ACTIVATION AND SAFETY IN MODIFIED COHORT OF TG01 TRIAL IN RESECTED PANCREATIC CANCER PATIENTS.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below